ArticleInflammopharmacology2025
Ocimene mitigates pyroptosis through TLR4/NLRP3-mediated mechanisms in CFA-induced inflammation.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Essential Oil ofPlants (Basel, Switzerland) · 2026Review
- Article
- Celastrol suppresses bone destruction in rheumatoid arthritis by inhibiting ALOX5 expression in macrophages via the NF-κB pathway.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The monocyclic monoterpenoid ocimene (OC) has undergone pharmacological testing as a possible inhibitor of pyroptosis triggered by TLR4/NLRP3 pathway, involved in progression of several diseases, such as rheumatoid arthritis (RA), inflammation, and chronic pain. Arthritis was evaluated using formaldehyde-induced arthritis rat model. Potential targets of OC against adjuvant-induced arthritis (AIA) in rats were examined using pharmacological testing and an integrative research strategy. CFA (o.1 ml) was used to assess the anti-arthritic effects of OC during a 28-day study period. To ascertain the therapeutic effects and identify pharmacological mechanisms, a variety of techniques were used, including macroscopic examination, gene expression profiling using PCR, an estimate of PGE-2, anti-CCP, 5-LOX besides markers of oxidative stress via ELISA, as well as radiographic examination. Oral administration of OC (50, 100, and 200 mg/kg) significantly (p < 0.001) decreased paw edema in the formaldehyde-induced arthritis. Inhibition of the NLRP3 inflammasome led to a significant downregulation of NFκB, caspase-1, and ASC, a decrease in the release of IL-1β and IL-18, and a modulation of GSDMD-mediated pyroptosis, hence reducing bone erosion and joint inflammation by blocking TLR4/NLRP3/GSDMD signaling. Levels of IL-4 and IL-10 were elevated in comparison to the disease control group. In addition, ELISA revealed that levels of the primary mediators of inflammation PGE-2 and 5-LOX, as well as malondialdehyde (MDA), a marker of oxidative stress, were significantly lower in the treated rats. In contrast, other antioxidant markers, such as glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD), were upregulated following the treatment. In addition, OC altered the actions of the COX enzyme, which reduced inflammation and eased RA-related discomfort. Therefore, it can be concluded that OC exhibited anti-arthritic attributes via modulation of TLR4/NLRP3/GSDMD signaling-mediated pyroptosis.
Indexed as
Identifiers
40266533What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.